Fourth Bioelectronic Medicine Summit Showcases Broad Innovation

Some of the most influential international experts, researchers, and scientific minds participated in the Fourth Bioelectronic Medicine Summit: Technology Targeting Molecular Mechanisms, hosted by The Feinstein Institutes for Medical Research – the global scientific home of bioelectronic medicine – on September 23 and 24.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005523/en/

Drs. Kevin Tracey, Valentin Pavlov, Sangeeta Chavan welcome participants to the 2020 Bioelectronic Medicine Summit (Credit: Feinstein Institutes)

Bioelectronic medicine combines molecular medicine, neuroscience, and biomedical engineering to develop innovative therapies to treat a variety of diseases and conditions through targeted stimulation of nerves, including paralysis, arthritis, pulmonary hypertension, and inflammatory bowel disease. Due to coronavirus disease 2019 (COVID-19), this year’s summit was held virtually and drew nearly 200 attendees, including esteemed academic leaders, members of the media, and industry professionals.

“Even though our recent focus has been on discovering a COVID-19 treatment, we continue

Read More

Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Fourth Intermediate People’s Court of Beijing (“Beijing Fourth Court”) issued a judgement holding Sinobioway Bio-medicine Co., Ltd. (“Sinobioway Medicine”) and Mr. Aihua Pan (collectively, “the Defendants”) liable for torts and breaches of shareholder fiduciary duty.

The judgment follows a complaint filed by Sinovac Biotech (Hong Kong) Ltd. (“Sinovac Hong Kong”) on May 16, 2018 against Sinobioway Medicine, Mr. Aihua Pan, and Shandong Sinobioway Biomedicine Co., Ltd. to hold them jointly liable for the offenses they committed during an attempt to take physical control of Sinovac’s Shangdi facility in Beijing on April 17, 2018.

The Beijing Forth Court found that the Defendants disrupted Sinovac Beijing’s production by cutting power, which resulted in Sinovac Beijing being forced to

Read More